| MYD88 L265P somatic mutation in Waldenström's macroglobulinemia SP Treon, L Xu, G Yang, Y Zhou, X Liu, Y Cao, P Sheehy, RJ Manning, ... New England Journal of Medicine 367 (9), 826-833, 2012 | 1356 | 2012 |
| Ibrutinib in previously treated Waldenström’s macroglobulinemia SP Treon, CK Tripsas, K Meid, D Warren, G Varma, R Green, ... New England Journal of Medicine 372 (15), 1430-1440, 2015 | 901 | 2015 |
| The genomic landscape of Waldenström macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B … ZR Hunter, L Xu, G Yang, Y Zhou, X Liu, Y Cao, RJ Manning, C Tripsas, ... Blood, The Journal of the American Society of Hematology 123 (11), 1637-1646, 2014 | 462 | 2014 |
| MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele … L Xu, ZR Hunter, G Yang, Y Zhou, Y Cao, X Liu, E Morra, A Trojani, ... Blood, The Journal of the American Society of Hematology 121 (11), 2051-2058, 2013 | 427 | 2013 |
| Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenström macroglobulinemia SP Treon, Y Cao, L Xu, G Yang, X Liu, ZR Hunter Blood, The Journal of the American Society of Hematology 123 (18), 2791-2796, 2014 | 378 | 2014 |
| A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia G Yang, Y Zhou, X Liu, L Xu, Y Cao, RJ Manning, CJ Patterson, ... Blood, The Journal of the American Society of Hematology 122 (7), 1222-1232, 2013 | 374 | 2013 |
| Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the FcγRIIIa-158 V/V and V/F polymorphism E Hatjiharissi, L Xu, DD Santos, ZR Hunter, BT Ciccarelli, S Verselis, ... Blood, the Journal of the American Society of Hematology 110 (7), 2561-2564, 2007 | 290 | 2007 |
| MYD88 mutations and response to ibrutinib in Waldenström's macroglobulinemia SP Treon, L Xu, Z Hunter New England Journal of Medicine 373 (6), 584-586, 2015 | 250 | 2015 |
| The WHIM-like CXCR4S338X somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom’s Macroglobulinemia Y Cao, ZR Hunter, X Liu, L Xu, G Yang, J Chen, CJ Patterson, ... Leukemia 29 (1), 169-176, 2015 | 222 | 2015 |
| Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248 SP Treon, ZR Hunter, J Matous, RM Joyce, B Mannion, R Advani, D Cook, ... Clinical cancer research 13 (11), 3320-3325, 2007 | 213 | 2007 |
| Characterization of familial Waldenström's macroglobulinemia SP Treon, ZR Hunter, A Aggarwal, EP Ewen, S Masota, C Lee, DD Santos, ... Annals of Oncology 17 (3), 488-494, 2006 | 213 | 2006 |
| Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenstrom macroglobulinemia treated with nucleoside analogs X Leleu, J Soumerai, A Roccaro, E Hatjiharissi, ZR Hunter, R Manning, ... Journal of Clinical Oncology 27 (2), 250-255, 2009 | 182 | 2009 |
| Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia SP Treon, CK Tripsas, K Meid, S Kanan, P Sheehy, S Chuma, L Xu, ... Blood, The Journal of the American Society of Hematology 124 (4), 503-510, 2014 | 178 | 2014 |
| Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia SP Treon, AR Branagan, Z Hunter, D Santos, O Tournhilac, KC Anderson Annals of Oncology 15 (10), 1481-1483, 2004 | 170 | 2004 |
| Ibrutinib monotherapy in symptomatic, treatment-naïve patients with Waldenström macroglobulinemia SP Treon, J Gustine, K Meid, G Yang, L Xu, X Liu, M Demos, A Kofides, ... Journal of clinical oncology 36 (27), 2755-2761, 2018 | 158 | 2018 |
| Thalidomide and rituximab in Waldenstrom macroglobulinemia SP Treon, JD Soumerai, AR Branagan, ZR Hunter, CJ Patterson, ... Blood, The Journal of the American Society of Hematology 112 (12), 4452-4457, 2008 | 150 | 2008 |
| Lenalidomide and rituximab in Waldenstrom's macroglobulinemia SP Treon, JD Soumerai, AR Branagan, ZR Hunter, CJ Patterson, ... Clinical cancer research 15 (1), 355-360, 2009 | 149 | 2009 |
| Mast cells in Waldenstrom's macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling O Tournilhac, DD Santos, L Xu, J Kutok, YT Tai, S Le Gouill, L Catley, ... Annals of oncology 17 (8), 1275-1282, 2006 | 141 | 2006 |
| Targeting NF-κB in Waldenstrom macroglobulinemia X Leleu, J Eeckhoute, X Jia, AM Roccaro, AS Moreau, M Farag, A Sacco, ... Blood, The Journal of the American Society of Hematology 111 (10), 5068-5077, 2008 | 136 | 2008 |
| Overall survival and competing risks of death in patients with W aldenström macroglobulinaemia: an analysis of the S urveillance, E pidemiology and E nd R esults database JJ Castillo, AJ Olszewski, S Kanan, K Meid, ZR Hunter, SP Treon British Journal of Haematology 169 (1), 81-89, 2015 | 135 | 2015 |
